ANIP ANI Pharmaceuticals Inc.

ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November

ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November

PRINCETON, N.J., Nov. 04, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will present at at two upcoming investor conferences as follows:

• The Guggenheim Inaugural Healthcare Innovation Conference

Wednesday, November 13, 2024, at 10:00am ET

• The Jefferies London Healthcare Conference

Wednesday, November 20, 2024, at 2:30pm GMT/9:30am ET

The live and archived webcasts will be accessible from the Company’s website at , under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days.

About ANI Pharmaceuticals, Inc.

ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S.-based manufacturing; and its Established Brands business. For more information, visit .

Investor Relations:

Lisa M. Wilson, In-Site Communications, Inc.

T: 212-452-2793

E:

Source: ANI Pharmaceuticals, Inc.



EN
04/11/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on ANI Pharmaceuticals Inc.

 PRESS RELEASE

ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Finan...

ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook For full year 2024, the Company expects total net revenues, adjusted non-GAAP EBITDA, and adjusted non-GAAP diluted EPS to be at or above the guidance ranges provided on November 8, 2024Rare Disease Segment performed in line with expectations, with Purified Cortrophin Gel net revenues of $197.8 million to $198.4 million for the full year 2024 and ILUVIEN and YUTIQ net revenues of $30.4 million to $31.0 million for the post-acquisition period from September 16, 2024 to December 31,...

 PRESS RELEASE

ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopr...

ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company has launched Prucalopride Tablets. ANI’s Prucalopride Tablets is the generic version of the reference listed drug (RLD) Motegrity®. "We are delighted to build momentum early in 2025 with the approval of the fir...

 PRESS RELEASE

ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthca...

ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference PRINCETON, N.J., Dec. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer; Stephen Carey, Chief Financial Officer; and Dr. Mary Pao, Chief Medical Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15pm PST/5:15pm EST, in San Francisco. The live and archived webcast will be accessible from the Company’s website at , under the Inves...

ANI Pharmaceuticals Inc: 1 director

A director at ANI Pharmaceuticals Inc sold 7,500 shares at 55.790USD and the significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years ...

 PRESS RELEASE

ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare...

ANI Pharmaceuticals to Present at 36th Annual Piper Sandler Healthcare Conference PRINCETON, N.J., Nov. 26, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer, and Stephen Carey, Chief Financial Officer, will host a fireside chat at the 36th Annual Piper Sandler Healthcare Conference on Wednesday, December 4, 2024 at 3pm EST in NYC. The live and archived webcast will be accessible from the Company’s website at , under the Investors section under Events and Presentations. The...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch